CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
3.020
+0.080 (2.72%)
Mar 9, 2026, 4:00 PM EDT - Market closed
CNS Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Cash & Equivalents | 9.86 | 6.46 | 0.55 | 10.06 | 5 | 14.04 | Upgrade
|
| Cash & Short-Term Investments | 9.86 | 6.46 | 0.55 | 10.06 | 5 | 14.04 | Upgrade
|
| Cash Growth | 41.46% | 1077.53% | -94.54% | 100.93% | -64.35% | 93.88% | Upgrade
|
| Other Receivables | - | 0.88 | - | - | - | - | Upgrade
|
| Receivables | - | 0.88 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 1.48 | 1.29 | 0.84 | 2.51 | 2.47 | 1.46 | Upgrade
|
| Other Current Assets | 0.04 | 0.02 | 0.2 | - | - | - | Upgrade
|
| Total Current Assets | 11.39 | 8.66 | 1.59 | 12.56 | 7.48 | 15.5 | Upgrade
|
| Property, Plant & Equipment | 0 | 0.01 | 0 | 0.01 | 0.02 | 0.02 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | - | 0.33 | 0.33 | Upgrade
|
| Other Long-Term Assets | 0.47 | 0.04 | 0.1 | 0.48 | 0.93 | - | Upgrade
|
| Total Assets | 11.87 | 8.7 | 1.7 | 13.05 | 8.76 | 15.85 | Upgrade
|
| Accounts Payable | 1.93 | 2.2 | 5.83 | 4.51 | 1.98 | 0.95 | Upgrade
|
| Accrued Expenses | - | - | - | - | 0.22 | 0.52 | Upgrade
|
| Short-Term Debt | 0.03 | 0.33 | 0.3 | 0.41 | 0.39 | 0.44 | Upgrade
|
| Total Current Liabilities | 1.96 | 2.52 | 6.13 | 4.92 | 2.59 | 1.91 | Upgrade
|
| Total Liabilities | 1.96 | 2.52 | 6.13 | 4.92 | 2.59 | 1.91 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0.02 | Upgrade
|
| Additional Paid-In Capital | 104.23 | 90.6 | 65.13 | 58.85 | 41.6 | 34.87 | Upgrade
|
| Retained Earnings | -94.32 | -84.42 | -69.57 | -50.72 | -35.44 | -20.95 | Upgrade
|
| Shareholders' Equity | 9.91 | 6.18 | -4.43 | 8.13 | 6.16 | 13.95 | Upgrade
|
| Total Liabilities & Equity | 11.87 | 8.7 | 1.7 | 13.05 | 8.76 | 15.85 | Upgrade
|
| Total Debt | 0.03 | 0.33 | 0.3 | 0.41 | 0.39 | 0.44 | Upgrade
|
| Net Cash (Debt) | 9.83 | 6.14 | 0.25 | 9.65 | 4.62 | 13.6 | Upgrade
|
| Net Cash Growth | 41.65% | 2374.76% | -97.43% | 108.92% | -66.05% | 87.81% | Upgrade
|
| Net Cash Per Share | 31.48 | 192.61 | - | - | - | - | Upgrade
|
| Filing Date Shares Outstanding | 0.62 | 0.25 | - | - | - | - | Upgrade
|
| Total Common Shares Outstanding | 0.57 | 0.12 | - | - | - | - | Upgrade
|
| Working Capital | 9.43 | 6.13 | -4.54 | 7.64 | 4.88 | 13.59 | Upgrade
|
| Book Value Per Share | 17.25 | 52.43 | - | - | - | - | Upgrade
|
| Tangible Book Value | 9.91 | 6.18 | -4.43 | 8.13 | 6.16 | 13.95 | Upgrade
|
| Tangible Book Value Per Share | 17.25 | 52.43 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.